Clopidogrel does not benefit infants with congenital heart disease

06/19/2013 |

Clopidogrel therapy did not yield better outcomes for babies with cyanotic congenital heart disease and a systemic-to-pulmonary-artery shunt compared with placebo and conventional treatment, a study showed. Rates of death, overall bleeding and severe bleeding were similar for both clopidogel and placebo groups, researchers reported in the New England Journal of Medicine.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
Bend, OR
Clinical Appeals RN
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ